Bispecific antibody · Immune activation, directed at CD3 (CD3E) and MUC16 (CA125) (MUC16) · developed by REGENERON PHARMACEUTICALS
Ubamatamab is a bispecific human monoclonal antibody that binds human CD3 on T cells and MUC16 (CA125) on tumor cells. By cross-linking T cells to MUC16-expressing cells, it is intended to trigger a cytotoxic T-lymphocyte response against those cells. It is being studied in ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06787612 | Phase 2 | Ovarian Cancer | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →